Human Gene Set: GSE17721_PAM3CSK4_VS_GADIQUIMOD_1H_BMDC_UP


Standard name GSE17721_PAM3CSK4_VS_GADIQUIMOD_1H_BMDC_UP
Systematic name M3962
Brief description Genes up-regulated in comparison of dendritic cells (DC) stimulated with Pam3Csk4 (TLR1/2 agonist) at 1 h versus DC cells stimulated with Gardiquimod (TLR7 agonist) at 1 h.
Full description or abstract mouse primary BMDCs were stimulated with tlr ligands and gene expression changes were profiled on Affymetrix arrays
Collection C7: Immunologic Signature
      IMMUNESIGDB: ImmuneSigDB
Source publication Pubmed 19729616   Authors: Amit I,Garber M,Chevrier N,Leite AP,Donner Y,Eisenhaure T,Guttman M,Grenier JK,Li W,Zuk O,Schubert LA,Birditt B,Shay T,Goren A,Zhang X,Smith Z,Deering R,McDonald RC,Cabili M,Bernstein BE,Rinn JL,Meissner A,Root DE,Hacohen N,Regev A
Exact source GSE17721_1948_200_UP
Related gene sets (show 317 additional gene sets from the source publication)

(show 231 gene sets from the same authors)
External links
Filtered by similarity ?
Source species Mus musculus
Contributed by Jernej Godec (Dana-Farber Cancer Institute)
Source platform or
identifier namespace		 HUMAN_GENE_SYMBOL
Dataset references (show 1 datasets)
Download gene set format: grp | gmt | xml | json | TSV metadata
Compute overlaps ? (show collections to investigate for overlap with this gene set)
Compendia expression profiles ? NG-CHM interactive heatmaps
(Please note that clustering takes a few seconds)
GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)

Legacy heatmaps (PNG)
GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)
Advanced query Further investigate these 200 genes
Gene families ? Categorize these 200 genes by gene family
Show members (show 200 source identifiers mapped to 200 genes)
Version history 7.3: Moved to ImmuneSigDB sub-collection.

See MSigDB license terms here. Please note that certain gene sets have special access terms.